Acuitas Therapeutics Named Canada’s Top Small and Medium Employers in 2026

Vancouver, B.C. – Acuitas Therapeutics, the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, has been named one of Canada’s Top Small & Medium Employers in 2026 for the third year in a row. A recipient of the BC’s Top Employers (2025) and Canada’s Most Admired™ Corporate Cultures (2024), this award highlights Acuitas’ achievement as a top-performing small and medium employer, demonstrating that organizations of its size can set the standard for innovation, inclusivity, and culture.

“This award is a testament to the way our teams work – closely, collaboratively, and with a shared commitment to scientific excellence,” said Tom Madden, CEO of Acuitas Therapeutics. “That foundation gives us the agility to respond quickly to complex challenges and apply our LNP platform in ways that truly make a difference for our partners. It speaks to the commitment and care our team brings to their work every day and the environment of mutual respect and support that exists throughout Acuitas.”

Read the full list of Canada’s Top Small & Medium Employers here.

About Acuitas Therapeutics

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.    

Acuitas’ clinically validated LNP technology has had a profound global impact – most notably enabling the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. The technology also enables ONPATTRO® by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy.   

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic and in vivo CAR T-cell therapies, epigenetic medicines to modulate gene expression without altering DNA, multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.    

For more information, visit www.acuitastx.com. 

-END-